Kettering Health - Tracking Gliomas with Precision Medicine

Kettering Health is breaking new ground in the fight against brain cancer with a targeted research effort focused on gliomas - aggressive tumors with limited treatment options and a 10% five-year survival rate. With funding from the Gala of Hope Foundation, Kettering researchers are engaged in a Phase 2 Animal Trial to study how these tumors change over time, aiming to develop more accurate tools for diagnosis, monitoring, and personalized care.

Working in close partnership with Dayton Children’s Hospital and its Living Biobank, Kettering is combining tissue samples with advanced imaging and molecular analysis to better understand the biological signatures of glioma behavior. This knowledge will hopefully drive a Phase 3 Clinical Trial in human patients and could enable doctors to anticipate recurrence, tailor treatments, and avoid unnecessary interventions - offering patients more clarity and control in their cancer journey.

By translating laboratory discoveries into clinical insights, Kettering Health is playing a critical role in turning regional collaboration into real-world progress - and helping lead a shift toward smarter, more responsive brain cancer care.

https://ketteringhealth.org/braintumor/?gad_source=1&gad_campaignid=17809382569&gbraid=0AAAAABTlnyfVh1-SqPPF9Tdmi4NizPibC&gclid=CjwKCAjwiezABhBZEiwAEbTPGNrehucLB9K9oRPsz9NkYrEffAVen88QXsue-TZ4pSDG72Mdfx1QGhoCv6oQAvD_BwE